

University of Minnesota Formulary Updates



October 2025

TRADE NAME (generic name)	Brand/ Generic Product	Effective Date	Description of Change
AYVAKIT (avapritinib tab 100 mg)	Brand	7/1/2025	Move to Tier 3
AYVAKIT (avapritinib tab 200 mg)	Brand	7/1/2025	Move to Tier 3
AYVAKIT (avapritinib tab 25 mg)	Brand	7/1/2025	Move to Tier 3
AYVAKIT (avapritinib tab 300 mg)	Brand	7/1/2025	Move to Tier 3
AYVAKIT (avapritinib tab 50 mg)	Brand	7/1/2025	Move to Tier 3
BRILINTA (ticagrelor tab 60 mg)	Brand	10/1/2025	Move to Tier 3, generics available
BRILINTA (ticagrelor tab 90 mg)	Brand	10/1/2025	Move to Tier 3, generics available
CTEXLI (chenodiol tab 250 mg)	Brand	3/16/2025	Addition, Tier 1
LANTUS (insulin glargine inj 100 unit/ml)	Brand	8/1/2025	Addition, Tier 1
LANTUS SOLOSTAR (insulin glargine soln pen-injector 100 unit/ml)	Brand	8/1/2025	Addition, Tier 1
OMVOH (mirikizumab-mrkz subcutaneous auto-inj 100 mg/ml & 200mg/2ml)	Brand	10/1/2025	Addition, Tier 2
OMVOH (mirikizumab-mrkz subcutaneous pref syr 100 mg/ml & 200mg/2ml)	Brand	10/1/2025	Addition, Tier 2
PRETOMANID (pretomanid tab 200 mg)	Brand	10/1/2025	Addition, Tier 2
RIBAVIRIN (ribavirin cap 200 mg)	Brand	10/1/2025	Addition, Tier 1
RIBAVIRIN (ribavirin tab 200 mg)	Brand	10/1/2025	Addition, Tier 1
SEMGLEE (insulin glargine-yfgn inj 100 unit/ml)	Brand	8/1/2025	Move to Tier 3
SEMGLEE (insulin glargine-yfgn soln pen-injector 100 unit/ml)	Brand	8/1/2025	Move to Tier 3
SIRTURO (bedaquiline fumarate tab 100 mg (base equiv))	Brand	10/1/2025	Addition, Tier 2
SIRTURO (bedaquiline fumarate tab 20 mg (base equiv))	Brand	10/1/2025	Addition, Tier 2
VUMERITY (dioxime fumarate capsule delayed release 231 mg)	Brand	7/1/2025	Move to Tier 3